Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders

Arthritis and Rheumatism

Volumn 44, Issue 5, 2001, Pages 1143-1148

  Cracowski, Jean Luc ^a   Marpeau, Claudine ^a   Carpentier, Patrick H ^b   Imbert, Bernard ^b   Hunt, Mark ^a   Stanke Labesque, Françoise ^a   Bessard, Germain ^a  

^a UNIV GRENOBLE ALPES   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ANTIOXIDANT; ARACHIDONIC ACID; CREATINE; FREE RADICAL; ISOPROSTANE; LIPID; PROSTAGLANDIN F2; PROSTAGLANDIN F2 ALPHA;

ADULT; AGED; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SCLERODERMA; SYSTEMIC SCLEROSIS; URINALYSIS;

EID: 0035026422     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200105)44:5<1143::aid-anr196>3.0.co;2-%23     Document Type: Article

References (46)

1. Maricq HR. The microcirculation in scleroderma and allied diseases. Adv Microcirc 1982;10:17-52.
2. Maricq HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AI, et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989;32:998-1006.
3. Maricq HR. Scleroderma spectrum disorders, not systemic sclerosis spectrum [letter]. J Rheumatol 1997;24:1454.
4. Leroy EC, Black C, Fleischmajer R, Jahlonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
6. Furst DE, Clements PJ. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol Suppl 1997;48:53-7.
7. Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S, et al. Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999;112:78-84.
8. Murrell DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993;28:78-85.
9. Emerit I, Filipe P, Meunier P, Auclair C, Freitas J, Deroussent A, et al. Clastogenic activity in the plasma of scleroderma patients: a hiomarker of oxidative stress. Dermatology 1997;194:140-6.
10. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990;87:9383-7.
11. Souvignet C, Cracowski JL, Stanke F, Bessard G. Are isoprostanes a clinical marker for antioxidant drug investigation? Fundam Clin Pharmacol 2000;14:1-10.
12. 2α: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br J Clin Pharmacol 1996;42:15-9.
13. Ames PR, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh J. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology (Oxford) 1999;38: 529-34.
14. Stein CM, Tanner SB, Awad JA, Roberts LJ II. Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996;39:1146-50.
15. Carpentier PH, Maricq HR. Mierovaseulature in systemic sclerosis. Rheum Dis Clin North Am 1990;16:75-91.
16. 2-isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: development of a solid-phase extraction procedure. J Chromatogr B Biomed Appl 1995;667:199-208.
17. Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 1997;185:71-9.
18. Lau CS, Bridges AB, Muir A, Scott N, Bancroft A, Belch JJ. Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon. Br J Rheumatol 1992;31: 375-80.
19. Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C, et al. Oxidative stress in systemic sclerosis. Mol Cell Biochem 1999;196:85-91.
20. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 1994;21:1477-83.
21. Moore K, Roberts LJ II. Measurement of lipid peroxidation. Free Radic Res 1998;28:659-71.
22. Rokach J, Khanapure SP, Hwang SW, Adiyaman M, Lawson JA, Fitzgerald GA. Nomenclature of isoprostanes: a proposal. Prostaglandins 1997;54:853-73.
23. Roberts LJ II, Morrow JD. The generation and action of isoprostanes. Biochim Biophys Acta 1997;1345:121-35.
24. Richelle M, Turini ME, Guidoux R, Tavazzi I, Metairon S, Fay LB. Urinary isoprostane excretion is not confounded by the lipid content of the diet. FEBS Lett 1999;459:259-62.
25. Jourdan K, Mitchell J, Evans T. Release of isoprostanes by human pulmonary artery in organ culture: a cyclo-oxygenase and nitric oxide dependent pathway. Biochem Biophys Res Commun 1997; 233:668-72.
26. 2α in vitro and in vivo via the cyclooxygenases. J Pharmacol Exp Ther 1997;282:1658-65.
27. 2α is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:3230-5.
28. 2a and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999;99: 224-9.
29. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995;368:225-9.
30. 2α during cyclo-oxygenase inhibition in rats but not in man. Br J Pharmacol 1997;121:1770-4.
31. Reilly M, Delanty N, Lawson JA, Fitzgerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996;94:19-25.
32. 2-isoprostanes in atopic asthmatics. Am J Respir Crit Care Med 1999;160:1947-51.
33. 2α excretion in man. J Pharmacol Exp Ther 1995; 275:94-100.
34. Li H, Lawson JA, Reilly M, Adiyaman M, Hwang SW, Rokach J, et al. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine. Proc Natl Acad Sci U S A 1999;96: 13381-6.
35. 2α: an index for oxidative injury via free radical catalysed peroxidation. Prostaglandins Leukot Essent Fatty Acids 1998;58:319-25.
36. Murrell GA, Francis MJ, Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 1990;265:659-65.
37. Auch-Schwelk W, Katusic ZS, Vanhoutte PM. Contractions to oxygen-derived free radicals are augmented in aorta of the spontaneously hypertensive rat. Hypertension 1989;13:859-64.
38. Tate RM, Morris HG, Schroeder WR, Repine JE. Oxygen metabolites stimulate thromboxane production and vasoconstriction in isolated saline-perfused rabbit lungs. J Clin Invest 1984;74:608-13.
39. 2α. Br J Pharmacol 1996;119: 1276-80.
40. 2α). Eur J Pharmacol 2000;397:161-8.
41. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 1992;44:155-63.
42. Iuliano L, Pratico D, Ferro D, Pittoni V, Valesini G, Lawson J, et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997;90:3931-5.
43. Pratico D, Ferro D, Iuliano L, Rokach J, Conti F, Valesini G, et al. Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood 1999;93: 3401-7.
44. Catella F, Healy D, Lawson JA, FitzGerald GA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A 1986;83:5861-5.
45. Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987;47:647-56.
46. Denton CP, Bunce TD, Darado MB, Roberts Z, Wilson H, Howell K, et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology (Oxford) 1999;38:309-15.